



## **PRESS RELEASE**

Published: 2025-12-04

### **Inhalation Sciences receives purchase order worth 160 KEUR from international distributor for the US market**

Inhalation Sciences AB (ISAB) has received a purchase order worth 160 KEUR (1.756 MSEK) from an international distributor for the US market. The new order is for the PreciseInhale® platform, ISAB's unique aerosol generation system. The end customer is a global pharmaceutical company based in the US.

PreciseInhale® is unique within inhaled drug development as a 'precision dosing' system. Unlike standard 'tower testing' systems, it customizes the individual aerosol dose to individual test animals, achieving exceptionally high-precision and predictive data in the preclinical stages of inhaled drug development.

With this order and upcoming collaboration, ISAB expands its operations and unique technology into the important US market. The US is a priority market for ISAB, as the FDA's latest guidelines increasingly emphasize advanced in vitro methods and dissolution testing for inhaled drugs. These regulatory developments support ISAB's technology platform, including PreciseInhale® and DissolvIt®, and are driving growing demand for physiologically relevant, animal-sparing test systems.

ISAB CEO Manoush Masarrat: "We are thrilled to secure this significant order and partner with a leading global pharmaceutical company in the US. This marks an exciting expansion of PreciseInhale® into North America, a key market for inhaled drug innovation."

#### **For more information, please contact:**

Manoush Masarrat, CEO

Phone: +46 (0) 73 628 9153

E-mail: [manoush.masarrat@inhalation.se](mailto:manoush.masarrat@inhalation.se)

#### **About Inhalation Sciences Sweden AB (publ)**

Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.

*This disclosure contains information that Inhalation Sciences is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on December 4, 2025 at 11:20.*